Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 33,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans

NCT02974699
View directory record Official record
Conditions
Type II Diabetes
Interventions
Potato Starch (Bob's Red Mill), Pregelatinized Starch (Resource ThickenUp)
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 19, 2026, 7:42 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Simethicone as Part of ERAS in Bariatric Surgery Patients

NCT06812832
View directory record Official record
Conditions
Simethicone, Bariatric Surgery, Post-operative Pain
Interventions
Simethicone 80 MG, Placebo
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

NCT00333398
View directory record Official record
Conditions
Influenza
Interventions
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
10
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site

NCT00781898
View directory record Official record
Conditions
Opiate Addiction
Interventions
Depot naltrexone, Treatment as Usual (TAU)
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 19, 2026, 7:42 PM EDT
Terminated Not applicable Interventional

Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy

NCT02798393
View directory record Official record
Conditions
Neuropathy
Interventions
Infrared Phototherapy, Sham
Other
Lead sponsor
Healthlight, LLC
Industry
Eligibility
25 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Topeka, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke

NCT02442804
View directory record Official record
Conditions
Stroke
Interventions
POMx, Placebo
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 19, 2026, 7:42 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion

NCT03508804
View directory record Official record
Conditions
Pain
Interventions
Lidocaine-Prilocaine Cream, Placebo Cream, 1% Lidocaine Paracervical Block
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

NCT02109406
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD2115 Dose 1, AZD 2115, Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Clearwater, Florida • Charleston, South Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

NCT01932606
View directory record Official record
Conditions
Heart Disease, Heart Failure With Preserved Ejection Fraction, Exercise Intolerance, Pulmonary Hypertension
Interventions
Nitrite, Saline Placebo for Nitrite
Drug
Lead sponsor
Barry Borlaug
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 19, 2026, 7:42 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

NCT01951638
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
View directory record Official record
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain

NCT01598207
View directory record Official record
Conditions
Chest Pain
Interventions
Marinol, Placebo
Drug
Lead sponsor
Yehudith Assouline-Dayan
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 19, 2026, 7:42 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Disease
Interventions
Nordlys SWT IPL, Meibomian Gland Expression (MGX), Sham Nordlys SWT IPL
Device · Procedure
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044
View directory record Official record
Conditions
Overt Hepatic Encephalopathy
Interventions
40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
34
States / cities
Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia

NCT00354809
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Insomnia
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Glendale, Arizona • Glendale, California • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

NCT04779216
View directory record Official record
Conditions
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions
Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg
Drug
Lead sponsor
Karen Klahr Miller, MD
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of PeptiSleep on Sleep Quality in Healthy Adults

NCT07258433
View directory record Official record
Conditions
Sleep, Wearable Technology, Cortisol, Healthy Participants, Cognitive Abilities
Interventions
PeptiSleep, Micro-crystalline cellulose
Dietary Supplement
Lead sponsor
Nuritas Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 19, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549
View directory record Official record
Conditions
Septic Shock
Interventions
LB1148, Placebo
Drug
Lead sponsor
Leading BioSciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
North Hollywood, California • San Diego, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 19, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT04683848
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
MT-3921, Placebo
Biological
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 19, 2026, 7:42 PM EDT